{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:10:37Z","timestamp":1787760637962,"version":"build-2784847793"},"reference-count":123,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.esmoop.2021.100153","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T20:38:52Z","timestamp":1620679132000},"page":"100153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)\/Associazione Medici Diabetologi (AMD)\/Societ\u00e0 Italiana Endocrinologia (SIE)\/Societ\u00e0 Italiana Farmacologia (SIF) multidisciplinary consensus position paper"],"prefix":"10.1016","volume":"6","author":[{"given":"N.","family":"Silvestris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Argentiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Natalicchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"D'Oronzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.D.","family":"Beretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Acquati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Adinolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Di Bartolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Faggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Morviducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tuveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Zatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Montagnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Giorgino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2021.100153_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canep.2016.01.003","article-title":"Obesity and cancer: an update of the global impact","volume":"41","author":"Arnold","year":"2016","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.esmoop.2021.100153_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1470-2045(14)71123-4","article-title":"Global burden of cancer attributable to high body-mass index in 2012: a population-based study","volume":"16","author":"Arnold","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib3","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer \u2013 viewpoint of the IARC Working Group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100153_bib4","first-page":"88","article-title":"Global patterns in excess body weight and the associated cancer burden","volume":"69","author":"Sung","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2021.100153_bib5","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","article-title":"Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies","volume":"371","author":"Renehan","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2021.100153_bib6","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0140-6736(09)60318-4","article-title":"Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies","volume":"373","author":"Whitlock","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2021.100153_bib7","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/archinte.165.11.1267","article-title":"Undertreatment of obese women receiving breast cancer chemotherapy","volume":"165","author":"Griggs","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.esmoop.2021.100153_bib8","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.2011.39.9436","article-title":"Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline","volume":"30","author":"Griggs","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib9","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1080\/0284186X.2019.1585942","article-title":"Obesity and chemotherapy administration: between empiric and mathematic method review","volume":"58","author":"Bouleftour","year":"2019","journal-title":"Acta Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1200\/JCO.2003.01.058","article-title":"Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel","volume":"21","author":"Smorenburg","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib11","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/bjc.2012.357","article-title":"Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents","volume":"107","author":"Chatelut","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2021.100153_bib12","first-page":"602","article-title":"Body composition measurement in severe obesity","volume":"8","author":"Das","year":"2005","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.esmoop.2021.100153_bib14","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1177\/1060028013509789","article-title":"Dosing considerations for obese patients receiving cancer chemotherapeutic agents","volume":"47","author":"Hall","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.esmoop.2021.100153_bib15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.clon.2020.05.004","article-title":"Obesity and cancer treatment outcomes: interpreting the complex evidence","volume":"32","author":"Slawinski","year":"2020","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.esmoop.2021.100153_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/17425255.2018.1440287","article-title":"Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters","volume":"14","author":"Smit","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.esmoop.2021.100153_bib18","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s13679-015-0169-4","article-title":"Overweight and obesity: prevalence, consequences, and causes of a growing public health problem","volume":"4","author":"Williams","year":"2015","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.esmoop.2021.100153_bib19","first-page":"s176","article-title":"Obesity: definition, comorbidities, causes, and burden","volume":"22","author":"Apovian","year":"2016","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.esmoop.2021.100153_bib20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrclinonc.2013.108","article-title":"Chemotherapy dosing in overweight and obese patients with cancer","volume":"10","author":"Lyman","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib21","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","article-title":"Simplified calculation of body-surface area","volume":"317","author":"Mosteller","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100153_bib22","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/j.1875-9114.2012.01108.x","article-title":"Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults","volume":"32","author":"Pai","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.esmoop.2021.100153_bib23","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.esmoop.2021.100153_bib24","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1517\/17425255.2011.570331","article-title":"The effects of obesity on drug pharmacokinetics in humans","volume":"7","author":"Morrish","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.esmoop.2021.100153_bib25","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1345\/aph.19381","article-title":"The origin of the \u2018ideal\u2019 body weight equations","volume":"34","author":"Pai","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.esmoop.2021.100153_bib26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40005-013-0073-4","article-title":"Obesity-related physiological changes and their pharmacokinetic consequences","volume":"43","author":"Cho","year":"2013","journal-title":"J\u00a0Pharm Invest"},{"key":"10.1016\/j.esmoop.2021.100153_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1079\/PNS2004403","article-title":"Obesity and metabolic disease: is adipose tissue the culprit?","volume":"64","author":"Frayn","year":"2005","journal-title":"Proc Nutr Soc"},{"key":"10.1016\/j.esmoop.2021.100153_bib28","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/ijo.2013.200","article-title":"Regulation of human subcutaneous adipose tissue blood flow","volume":"38","author":"Frayn","year":"2014","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.esmoop.2021.100153_bib29","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","article-title":"Effect of obesity on the pharmacokinetics of drugs in humans","volume":"49","author":"Hanley","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.esmoop.2021.100153_bib30","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/j.1552-4604.1986.tb02953.x","article-title":"Drug distribution and binding","volume":"26","author":"Oie","year":"1986","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.esmoop.2021.100153_bib31","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s13181-015-0488-6","article-title":"A\u00a0review of the toxicologic implications of obesity","volume":"11","author":"Zuckerman","year":"2015","journal-title":"J\u00a0Med Toxicol"},{"key":"10.1016\/j.esmoop.2021.100153_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/js980173a","article-title":"Pharmacokinetic considerations in obesity","volume":"88","author":"Blouin","year":"1999","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.esmoop.2021.100153_bib33","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3390\/ijms20092358","article-title":"Adipose tissue dysfunction as determinant of obesity-associated metabolic complications","volume":"20","author":"Longo","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.esmoop.2021.100153_bib34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11095-018-2551-x","article-title":"Pharmacokinetic and pharmacodynamic considerations for drugs binding to alpha-1-acid glycoprotein","volume":"36","author":"Smith","year":"2018","journal-title":"Pharm Res"},{"key":"10.1016\/j.esmoop.2021.100153_bib35","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1042\/cs0910679","article-title":"Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity","volume":"91","author":"Summers","year":"1996","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.esmoop.2021.100153_bib36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4161\/adip.27114","article-title":"Adipose tissue oxygenation: effects on metabolic function","volume":"3","author":"Hodson","year":"2014","journal-title":"Adipocyte"},{"key":"10.1016\/j.esmoop.2021.100153_bib37","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/sj.mn.7800206","article-title":"Impairment of hepatic microcirculation in fatty liver","volume":"10","author":"Ijaz","year":"2003","journal-title":"Microcirculation"},{"key":"10.1016\/j.esmoop.2021.100153_bib38","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1021\/acs.molpharmaceut.8b00159","article-title":"Nonalcoholic fatty liver disease and diabetes are associated with decreased CYP3A4 protein expression and activity in human liver","volume":"15","author":"Jamwal","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.esmoop.2021.100153_bib39","doi-asserted-by":"crossref","first-page":"15273","DOI":"10.1038\/s41598-018-33419-6","article-title":"Association between body mass index and fatty liver risk: a dose-response analysis","volume":"8","author":"Fan","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.esmoop.2021.100153_bib40","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2174\/1389200013338676","article-title":"Hepatic cytochrome P450 regulation in disease states","volume":"2","author":"Cheng","year":"2001","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.esmoop.2021.100153_bib41","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/clpt.2008.302","article-title":"Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics","volume":"85","author":"Morgan","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.esmoop.2021.100153_bib42","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1093\/ndt\/gfn379","article-title":"Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption","volume":"23","author":"Chagnac","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.esmoop.2021.100153_bib43","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clpt.2005.05.011","article-title":"Transporters and drug therapy: implications for drug disposition and disease","volume":"78","author":"Ho","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.esmoop.2021.100153_bib44","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s40262-017-0544-2","article-title":"Influence of morbid obesity on the pharmacokinetics of morphine, morphine-3-glucuronide, and morphine-6-glucuronide","volume":"56","author":"de Hoogd","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.esmoop.2021.100153_bib45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejca.2020.01.004","article-title":"Pharmacokinetics\/pharmacodynamic (PK\/PD) relationship of therapeutic monoclonal antibodies used in oncology: what's new?","volume":"128","author":"Mir","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2021.100153_bib46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2020.01.005","article-title":"Pharmacokinetic\/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers","volume":"128","author":"Paci","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2021.100153_bib47","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s11095-017-2259-3","article-title":"Pharmacokinetic considerations for antibody-drug conjugates against cancer","volume":"34","author":"Malik","year":"2017","journal-title":"Pharm Res"},{"key":"10.1016\/j.esmoop.2021.100153_bib48","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nrclinonc.2014.40","article-title":"Determining the optimal dose in the development of anticancer agents","volume":"11","author":"Mathijssen","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","article-title":"Impact of chemotherapy dose intensity on cancer patient outcomes","volume":"7","author":"Lyman","year":"2009","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.esmoop.2021.100153_bib50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000444543","article-title":"Neoadjuvant dose-dense and dose-intensified chemotherapy in breast cancer \u2013 review of the literature","volume":"11","author":"Reinisch","year":"2016","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.esmoop.2021.100153_bib51","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/S0140-6736(18)33137-4","article-title":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2021.100153_bib52","first-page":"1307","article-title":"Tumor size, sensitivity to therapy, and design of treatment schedules","volume":"61","author":"Norton","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.esmoop.2021.100153_bib53","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0002-9343(80)90472-6","article-title":"Dose: a critical factor in cancer chemotherapy","volume":"69","author":"Frei","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.esmoop.2021.100153_bib54","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199504063321401","article-title":"Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up","volume":"332","author":"Bonadonna","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100153_bib55","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1200\/JCO.2005.05.059","article-title":"Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial","volume":"23","author":"Bonneterre","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib56","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jnci\/90.16.1205","article-title":"Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B","volume":"90","author":"Budman","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2021.100153_bib57","first-page":"925","article-title":"Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer","volume":"28","author":"Crawford","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.esmoop.2021.100153_bib58","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.clbc.2018.02.003","article-title":"Chemotherapy dose intensity and overall survival among patients with advanced breast or ovarian cancer","volume":"18","author":"Denduluri","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.esmoop.2021.100153_bib59","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygyno.2012.12.017","article-title":"Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer","volume":"129","author":"Hanna","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib60","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-2407-11-131","article-title":"Evaluating the impact of relative total dose intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer \u2013 a pooled analysis","volume":"11","author":"Loibl","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2021.100153_bib61","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.12.019","article-title":"Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer","volume":"66","author":"Luciani","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2021.100153_bib62","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1200\/JCO.2003.05.002","article-title":"Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices","volume":"21","author":"Lyman","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib63","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.1996.14.11.3000","article-title":"Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and Leukemia Group B study 8541","volume":"14","author":"Rosner","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib64","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2018.05.004","article-title":"Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: a retrospective analysis from the PETACC 3 study","volume":"99","author":"Stocker","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2021.100153_bib65","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s12032-014-0881-z","article-title":"Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women","volume":"31","author":"Carroll","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib66","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/annonc\/mdr277","article-title":"Chemotherapy dose reductions in obese patients with colorectal cancer","volume":"23","author":"Chambers","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib67","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/S0140-6736(05)67110-3","article-title":"Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index","volume":"366","author":"Colleoni","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2021.100153_bib68","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/jnci\/87.5.361","article-title":"Obesity and therapy-related toxicity in patients treated for small-cell lung cancer","volume":"87","author":"Georgiadis","year":"1995","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2021.100153_bib69","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ygyno.2015.04.040","article-title":"The effect of weight-based chemotherapy dosing in a cohort of gynecologic oncology patients","volume":"138","author":"Hansen","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib70","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejca.2006.10.013","article-title":"Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer","volume":"43","author":"Jenkins","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2021.100153_bib71","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.clon.2016.02.003","article-title":"Febrile neutropenia rates according to body mass index and dose capping in women receiving chemotherapy for early breast cancer","volume":"28","author":"Lote","year":"2016","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.esmoop.2021.100153_bib72","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.2004.03.213","article-title":"Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study","volume":"22","author":"Lyman","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib73","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/028418601750071082","article-title":"Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area","volume":"40","author":"Poikonen","year":"2001","journal-title":"Acta Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib74","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2009.03.010","article-title":"Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA) > 2 m2","volume":"114","author":"Schwartz","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib75","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/cncr.11544","article-title":"Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma","volume":"98","author":"Meyerhardt","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2021.100153_bib76","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1200\/JCO.2004.07.121","article-title":"Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114","volume":"22","author":"Meyerhardt","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib77","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2008.02.023","article-title":"Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study","volume":"109","author":"Wright","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib78","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/annonc\/mdw315","article-title":"Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study","volume":"27","author":"Furlanetto","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib79","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1093\/annonc\/mdt294","article-title":"Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis","volume":"24","author":"Hourdequin","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib80","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3109\/10428194.2010.494315","article-title":"Body mass index and\u00a0outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma","volume":"51","author":"Jones","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.esmoop.2021.100153_bib81","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/sj.bmt.1703145","article-title":"Obesity and autologous stem cell transplantation in acute myeloid leukemia","volume":"28","author":"Meloni","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.esmoop.2021.100153_bib82","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nrclinonc.2013.108-c1","article-title":"Sarcopenia and chemotherapy dosing in obese patients","volume":"10","author":"Laviano","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib83","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1001\/jamaoncol.2019.4668","article-title":"Body composition, adherence to anthracycline and taxane-based chemotherapy, and survival after nonmetastatic breast cancer","volume":"6","author":"Cespedes Feliciano","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib84","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1158\/1078-0432.CCR-16-2266","article-title":"Body composition as a predictor of toxicity in patients receiving anthracycline and taxane-based chemotherapy for early-stage breast cancer","volume":"23","author":"Shachar","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100153_bib85","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00280-010-1288-y","article-title":"An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity","volume":"67","author":"Prado","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2021.100153_bib86","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10549-014-2843-8","article-title":"Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients","volume":"144","author":"Wong","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2021.100153_bib87","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1200\/JCO.2007.11.2938","article-title":"Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese","volume":"25","author":"Sparreboom","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib88","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1634\/theoncologist.2017-0167","article-title":"Fixed dosing of monoclonal antibodies in oncology","volume":"22","author":"Hendrikx","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2021.100153_bib89","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/annonc\/mdy408","article-title":"Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer","volume":"29","author":"Long","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib90","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.annonc.2019.10.015","article-title":"Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types","volume":"31","author":"Zhao","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib91","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/annonc\/mdy138","article-title":"Representation of obese participants in obesity-related cancer randomized trials","volume":"29","author":"Pestine","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib92","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/bcp.12323","article-title":"Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma","volume":"78","author":"Feng","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.esmoop.2021.100153_bib93","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/psp4.12143","article-title":"Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors","volume":"6","author":"Bajaj","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.esmoop.2021.100153_bib94","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.esmoop.2021.100153_bib95","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/psp4.12406","article-title":"Time-varying clearance and impact of disease state on the pharmacokinetics of avelumab in Merkel cell carcinoma and urothelial carcinoma","volume":"8","author":"Wilkins","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.esmoop.2021.100153_bib96","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejca.2020.01.003","article-title":"Pharmacokinetic\/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies","volume":"128","author":"Desnoyer","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2021.100153_bib97","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40425-017-0242-5","article-title":"Evaluation of dosing strategy for pembrolizumab for oncology indications","volume":"5","author":"Freshwater","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.esmoop.2021.100153_bib98","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1093\/annonc\/mdx235","article-title":"Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg\/kg dosing regimen in patients with advanced tumors","volume":"28","author":"Zhao","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib99","first-page":"1","article-title":"Expected and paradoxical effects of obesity on cancer treatment response","author":"Gallo","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.esmoop.2021.100153_bib100","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3390\/cancers12051230","article-title":"The effects of obesity on anti-cancer immunity and cancer immunotherapy","volume":"12","author":"Woodall","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2021.100153_bib101","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.3390\/nu11112704","article-title":"Leptin, obesity, and leptin resistance: where are we 25 years later?","volume":"11","author":"Izquierdo","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.esmoop.2021.100153_bib102","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2021.100153_bib103","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib104","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40425-019-0512-5","article-title":"Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition","volume":"7","author":"Naik","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.esmoop.2021.100153_bib105","doi-asserted-by":"crossref","first-page":"e0204729","DOI":"10.1371\/journal.pone.0204729","article-title":"Body mass index may predict the response to ipilimumab in metastatic melanoma: an observational multi-centre study","volume":"13","author":"Richtig","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2021.100153_bib106","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-019-0527-y","article-title":"A\u00a0multicenter study of body mass index in cancer patients treated with anti-PD-1\/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable","volume":"7","author":"Cortellini","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.esmoop.2021.100153_bib107","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12967-020-02404-x","article-title":"Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"18","author":"An","year":"2020","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.esmoop.2021.100153_bib108","doi-asserted-by":"crossref","first-page":"105745","DOI":"10.1016\/j.intimp.2019.105745","article-title":"The prognostic role of obesity is independent of sex in cancer patients treated with immune checkpoint inhibitors: a pooled analysis of 4090 cancer patients","volume":"74","author":"Xu","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.esmoop.2021.100153_bib109","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41574-019-0161-2","article-title":"The \u2018obesity paradox\u2019 in action with cancer immunotherapy","volume":"15","author":"Lysaght","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.esmoop.2021.100153_bib110","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1470-2045(19)30797-1","article-title":"Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study","volume":"21","author":"Sanchez","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib111","first-page":"491","article-title":"Low visceral fat content is a negative predictive marker for bevacizumab in metastatic colorectal cancer","volume":"38","author":"Miyamoto","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.esmoop.2021.100153_bib112","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/15384047.2017.1416938","article-title":"Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab","volume":"19","author":"Pizzuti","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.esmoop.2021.100153_bib113","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s12029-017-0047-2","article-title":"Bevacuzimab may be less effective in obese metastatic colorectal cancer patients","volume":"50","author":"Artac","year":"2019","journal-title":"J\u00a0Gastrointest Cancer"},{"key":"10.1016\/j.esmoop.2021.100153_bib114","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/cam4.490","article-title":"Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies","volume":"4","author":"Patel","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.esmoop.2021.100153_bib115","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1177\/1060028020902318","article-title":"Pharmacokinetics of trastuzumab after subcutaneous and intravenous administration in obese patients","volume":"54","author":"Gonzalez Garcia","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.esmoop.2021.100153_bib116","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1200\/JCO.2016.66.7311","article-title":"Body mass index and metastatic renal cell carcinoma: clinical and biological correlations","volume":"34","author":"Albiges","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib117","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/KCA-180047","article-title":"Targeted therapy and immunotherapy: effect of body mass index on clinical outcomes in patients diagnosed with metastatic renal cell carcinoma","volume":"3","author":"Bergerot","year":"2019","journal-title":"Kidney Cancer"},{"key":"10.1016\/j.esmoop.2021.100153_bib118","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00280-016-3232-2","article-title":"Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer","volume":"79","author":"Imai","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2021.100153_bib119","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00280-016-3146-z","article-title":"Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience","volume":"78","author":"Oda","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2021.100153_bib120","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bjh.14783","article-title":"Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors","volume":"182","author":"Molica","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.esmoop.2021.100153_bib121","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1592\/phco.29.9.1152","article-title":"Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia","volume":"29","author":"Pavlovsky","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.esmoop.2021.100153_bib122","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/diagnostics11010138","article-title":"Body mass index in patients treated with Cabozantinib for advanced renal cell carcinoma: a new prognostic factor?","volume":"11","author":"Santoni","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.esmoop.2021.100153_bib123","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/bcp.14334","article-title":"Population pharmacokinetics of regorafenib in solid tumours: exposure in clinical practice considering enterohepatic circulation and food intake","volume":"86","author":"Keunecke","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.esmoop.2021.100153_bib124","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/annonc\/mdn779","article-title":"Pharmacokinetics of sunitinib in an obese patient with a GIST","volume":"20","author":"Desar","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100153_bib125","article-title":"Impact of obesity on safety outcomes and treatment modifications with ado-trastuzumab emtansine in breast cancer patients","author":"Lee","year":"2020","journal-title":"J\u00a0Oncol Pharm Pract"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921001137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921001137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:26:21Z","timestamp":1761855981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921001137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":123,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2059702921001137"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100153","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)\/Associazione Medici Diabetologi (AMD)\/Societ\u00e0 Italiana Endocrinologia (SIE)\/Societ\u00e0 Italiana Farmacologia (SIF) multidisciplinary consensus position paper","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100153","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100153"}}